These findings extend understanding of the function of PGAM2 in myocardial hypertrophy, indicates that suppression of the elevated levels of PGAM2 may be a promising approach for treating Ang II-induced cardiac hypertrophy and diseases related to HSP90 aberrant regulation. The gene discussed is AGT; the disease is cardiac hypertrophy.